Please provide your email address to receive an email when new articles are posted on . Individuals who smoked had more genetic mutations associated with myelodysplastic syndrome than nonsmokers.
According to results from the IMerge trial, 2 39.8% of patients treated with imetelstat achieved 8 weeks of transfusion ...
Lupus-like manifestations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) represent a distinct inflammatory syndrome driven by clonal hematopoietic cells rather than ...
Please provide your email address to receive an email when new articles are posted on . Olutasidenib monotherapy or combination therapy may help certain patients with myelodysplastic syndrome achieve ...
RBC immunization is linked to reduced survival in transfusion dependent patients with myelodysplastic syndromes, independent ...
For Richard “Rocky” Kimball, a diagnosis of myelodysplastic syndromes, or MDS, necessitated a number of lifestyle changes.
In the first-line treatment of higher-risk myelodysplastic syndromes (MDS), the combination of venetoclax with azacitidine fell short of the primary endpoint of a reduction in mortality compared with ...
Credit: Geron. The approval was based on data from the phase 2/3 IMerge study. The Food and Drug Administration (FDA) has approved Rytelo ™ (imetelstat) for the treatment of adult patients with low- ...
Luspatercept significantly improved hemoglobin levels in non-transfusion-dependent patients with lower-risk myelodysplastic syndromes, potentially delaying transfusion needs. The study showed a 47.6% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results